2/7/2012

Although several entities have called for drug marketing restrictions or greater regulation of direct-to-consumer drug ads to be included in the Prescription Drug User Fee Act V (PDUFA V), there was just one mention of drug marketing during four-plus hours of testimony before the House Energy and Commerce Committee’s Subcommittee on Health at a Feb. 1 PDUFA V hearing. However, industry should not be lulled into thinking that these issues will not re-emerge as negotiations continue, according to Coalition for Healthcare Communication Executive Director John Kamp, who said “we’re watching carefully and remain prepared for a challenge.” Read more.

Full Story:
cohealthcom.org

Related Summaries